Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Pulmonary Embolism

NCT03108833 is registered in ClinicalTrials.gov with Tasly Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03108833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03108833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Pulmonary Embolism
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 6, 2017
Completion date
December 19, 2019
Enrollment
108 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute pulmonary embolism